These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9623326)

  • 1. [Considerations in rational use of tumor markers in breast carcinoma].
    Crombach G
    Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
    Einarsson R; Lindman H; Bergh J
    Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
    Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum marker combinations in human breast cancer (review).
    Lamerz R; Stieber P; Fateh-Moghadam A
    In Vivo; 1993; 7(6B):607-13. PubMed ID: 8193281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
    Schuurman JJ; Bong SB; Einarsson R
    Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum markers for breast cancer.
    Stenman UH; Heikkinen R
    Scand J Clin Lab Invest Suppl; 1991; 206():52-9. PubMed ID: 1947760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients.
    Tampellini M; Berruti A; Bitossi R; Gorzegno G; Alabiso I; Bottini A; Farris A; Donadio M; Sarobba MG; Manzin E; Durando A; Defabiani E; De Matteis A; Ardine M; Castiglione F; Danese S; Bertone E; Alabiso O; Massobrio M; Dogliotti L
    Breast Cancer Res Treat; 2006 Aug; 98(3):241-8. PubMed ID: 16670941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
    O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
    Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
    Zervoudis S; Peitsidis P; Iatrakis G; Panourgias E; Koureas A; Navrozoglou I; Dubois JB
    J BUON; 2007; 12(4):487-92. PubMed ID: 18067207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
    Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
    Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
    Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
    Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor markers in staging and prognosis of colorectal carcinoma.
    Levy M; Visokai V; Lipska L; Topolcan O
    Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of tumor markers during the follow-up of women without symptoms after treatment of primary breast cancer.
    Sauer H
    Anticancer Res; 1997; 17(4B):3059-61. PubMed ID: 9329601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human tetranectin: methodological and clinical studies.
    Høgdall CK
    APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
    Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
    Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum tumor markers in patients with breast cancer.
    Lumachi F; Basso SM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.